Protective Efficacy of an IST DNA vaccine with a CL264 molecular adjuvant against Toxoplasma gondii in a murine model

Kun-ping Ju,Y. C. Zhang,Zhihai Xu,Ling-yu Li,Huaiyu Zhou

DOI: https://doi.org/10.21203/rs.3.rs-3270569/v1

2023-01-01

Abstract:Abstract Background Toxoplasmosis, caused by the parasite Toxoplasma gondii ( T. gondii ), is a significant global zoonosis with devastating impacts. Despite its importance, an effective vaccine against toxoplasmosis for humans has not yet been developed. Vaccination remains the most cost-effective approach in combating this disease. Methods In this study, we designed and formulated a novel DNA vaccine encoding the inhibitor of STAT1 transcriptional activity (IST) of T. gondii utilizing the eukaryotic expression vector pEGFP-N1 for the first time. To enhance the immunoprotection of vaccine, we employed CL264, a TLR7 agonist, as a molecular adjuvant. The immunologic efficacy of this newly constructed vaccine was investigated in a murine model. Following intramuscular injection of the vaccine into mice, various indicators were assessed to evaluate the immune response, including antibodies, cytokines, and the proportion of CD4 + and CD8 + T cells. Additionally, two weeks after the third immunization, mice were challenged with highly virulent RH strain tachyzoites of T. gondii , and their survival time was observed. Results The vaccine demonstrated the ability to induce robust humoral and cellular immune responses in the immunized mice. Notably, TgIST-immunized mice exhibited prolonged survival time after T. gondii RH strain infection. Conclusions Our findings collectively demonstrate that the TgIST DNA vaccine elicits a significant immune response and offers partial protection against acute T. gondii infection in mice. These results suggest that TgIST holds potential as a candidate for further development as a DNA vaccine.